HFpEF Clinical Trials

46 recruitingLast updated: June 20, 2026

There are 46 actively recruiting hfpef clinical trials across 29 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Dallas, Texas, United States, Moscow, Russia, London, United Kingdom. Updated daily from ClinicalTrials.gov.


HFpEF Trials at a Glance

46 actively recruiting trials for hfpef are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Not Applicable with 12 trials, with the heaviest enrollment activity in Dallas, Moscow, and London. Lead sponsors running hfpef studies include King's College London, Manchester University NHS Foundation Trust, and National Medical Research Center for Cardiology, Ministry of Health of Russian Federation.

Treatments under study

About HFpEF Clinical Trials

Looking for clinical trials for HFpEF? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HFpEF trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HFpEF clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 46 trials

Recruiting
Early Phase 1

Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction (HFpEF)
University of Florida70 enrolled1 locationNCT07634640
Recruiting
Not Applicable

Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction

HFpEF
Universitaire Ziekenhuizen KU Leuven20 enrolled2 locationsNCT07270536
Recruiting
Not Applicable

ELEVATE-HFpEF Clinical Study

Heart Failure With Preserved Ejection Fraction (HFpEF)
Medtronic Cardiac Rhythm and Heart Failure700 enrolled44 locationsNCT06678841
Recruiting

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

Heart FailureCardiotoxicityMyocardial Infarction+12 more
Peerbridge Health, Inc2,000 enrolled8 locationsNCT06699056
Recruiting
Phase 2

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Cytokinetics60 enrolled25 locationsNCT06793371
Recruiting
Phase 2

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

HFpEF - Heart Failure With Preserved Ejection FractionFontan CirculationSingle Ventricle Heart Disease
Mayo Clinic27 enrolled1 locationNCT06762964
Recruiting

The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction (HFpEF)
University of Leicester130 enrolled1 locationNCT06768437
Recruiting
Phase 2

Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction

Coronary Artery DiseaseHeart Failure With Preserved Ejection Fraction (HFpEF)
King's College London350 enrolled1 locationNCT07560436
Recruiting
Phase 2

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

HFpEFMyocardial FibrosisLVDD
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation50 enrolled1 locationNCT06655480
Recruiting
Not Applicable

Muscle Blood Flow Regulation in HFpEF

HFpEF
VA Office of Research and Development35 enrolled1 locationNCT05115890
Recruiting

Predictors of Poor Prognosis in HFpEF

HFpEF
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation500 enrolled1 locationNCT06844032
Recruiting
Phase 1

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Heart Failure With Preserved Ejection Fraction (HFpEF)Heart
Vasa Therapeutics42 enrolled21 locationsNCT07219511
Recruiting
Phase 4

Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)

Group 2 Pulmonary HypertensionHFpEFHFmrEF+2 more
Gachon University Gil Medical Center64 enrolled15 locationsNCT07147114
Recruiting

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

renal dysfunctionHeart Failure With Preserved Ejection Fraction (HFpEF)Stage B Heart Failure
German Heart Institute600 enrolled1 locationNCT07185100
Recruiting

The Use of Advanced Imaging in HFpEF

Heart Failure With Preserved Ejection Fraction (HFpEF)
Sheffield Teaching Hospitals NHS Foundation Trust40 enrolled2 locationsNCT06905405
Recruiting
Phase 3

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.540 enrolled92 locationsNCT07288398
Recruiting
Not Applicable

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Heart Failure With Preserved Ejection Fraction (HFpEF)
Axon Therapies, Inc.150 enrolled20 locationsNCT04592445
Recruiting

AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices

Cardiovascular DiseasesHeart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Reduced Ejection Fraction (HFrEF)+2 more
University of Salerno205 enrolled1 locationNCT06909682
Recruiting

Prospective Evaluation of AI-ECG for SHD Detection

Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)Valvular Heart Disease Stenosis and Regurgitation (Diagnosis)Pulmonary Hypertension (Diagnosis)+1 more
Imperial College London590 enrolled5 locationsNCT07057466
Recruiting
Not Applicable

Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

Atrial Fibrillation (AF)Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Mildly Reduced Ejection Fraction+2 more
Nova Scotia Health Authority84 enrolled1 locationNCT07272902